GSK Gains Vaccine Adjuvant Technology With $300 Mil. Corixa Acquisition
GlaxoSmithKline will expand Corixa's vaccine adjuvant manufacturing capacity following the $300 mil. acquisition of the biotech company
GlaxoSmithKline will expand Corixa's vaccine adjuvant manufacturing capacity following the $300 mil. acquisition of the biotech company